Related Experiment Video
Updated: Feb 14, 2026

Author Spotlight: Efficacy of Auricular Pressure Bean Therapy in Reducing Wheezing Symptoms
Published on: May 10, 2024
Chronic Obstructive Pulmonary Disease. A Biomarker and a Potential Therapy
1Mt. Sinai West, St. Luke's Hospitals, and Mt. Sinai Icahn School of Medicine, New York, New York.
Alpha-1 antitrypsin deficiency causes emphysema by increasing lung elastin degradation. Biomarkers like desmosine show augmentation therapy preserves lung density, suggesting hyaluronan may offer therapeutic benefits for COPD.
Area of Science:
- Cardiorespiratory Medicine
- Pulmonary Disease Research
- Biomarker Discovery
Background:
- Advances in cardiorespiratory medicine trace back to 1956 Nobel Prize discoveries.
- Alpha-1 antitrypsin deficiency identified as a genetic cause of pulmonary emphysema.
- Neutrophil elastase inhibitor deficiency leads to lung elastin degradation and emphysema.
Purpose of the Study:
- To assess developments in cardiorespiratory medicine, focusing on chronic obstructive pulmonary disease (COPD).
- To explore the role of biomarkers in monitoring elastin degradation.
- To evaluate the therapeutic potential of hyaluronan aerosol in COPD.
Main Methods:
- Investigated alpha-1 antitrypsin deficiency and its link to pulmonary emphysema.
- Utilized desmosine and isodesmosine as biomarkers for elastin degradation.
- Analyzed data from the RAPID study on augmentation therapy for alpha-1 antitrypsin deficiency.
- Examined the effect of hyaluronan aerosol on elastin degradation in COPD lungs.
Main Results:
- Discovery of alpha-1 antitrypsin deficiency accelerated understanding of emphysema.
- Desmosine and isodesmosine serve as accurate biomarkers for elastin degradation.
- Augmentation therapy in alpha-1 antitrypsin deficiency reduces elastic tissue degradation.
- The RAPID study showed preserved lung density with decreased desmosine/isodesmosine levels.
- Hyaluronan aerosol demonstrated potential to block elastin degradation in COPD.
Conclusions:
- Biomarker insights support the potential of agents preventing lung elastin degradation.
- Hyaluronan aerosol may hold therapeutic promise for chronic obstructive pulmonary disease.
More Related Videos
04:59Heat-sensitive Moxibustion as a Traditional Chinese Medicine Therapy for Chronic Obstructive Pulmonary Disease Combined with Insomnia
Published on: May 30, 2025
08:17Generation of a Chronic Obstructive Pulmonary Disease Model in Mice by Repeated Ozone Exposure
Published on: August 25, 2017
Related Concept Videos
Chronic Obstructive Pulmonary Disease
Smoking is a primary risk factor for COPD, with over 80% of patients having a history of it. Patients typically experience progressive dyspnea or labored breathing, frequent coughing, and recurrent pulmonary infections. Many eventually succumb to respiratory failure, characterized by...
Chronic Obstructive Pulmonary Disease-II: Pathophysiology
Chronic Inflammation
Chronic Obstructive Pulmonary Disease-I: Introduction
Chronic Obstructive Pulmonary Disease-V: Management
Smoking Cessation
Chronic Obstructive Pulmonary Disease-V: Nursing Management
Assessment
Chronic Obstructive Pulmonary Disease-III: Symptoms and Complications.
Symptoms of COPD can be classified as primary or systemic. Primary symptoms relate to reduced airflow, while systemic or extrapulmonary symptoms relate to COPD's broader impact on the body.
Primary Symptoms of COPD: